IGC Pharma, Inc. (IGC) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1155931,
    "name": "IGC Pharma, Inc.",
    "stock_name": "IGC Pharma, Inc.",
    "full_name": "IGC Pharma, Inc.",
    "name_url": "stocks-analysis/igc-pharma-inc",
    "exchange": 215,
    "exchangecode": "ASE",
    "country_id": 2,
    "currency": "USD",
    "cmp": "0.31",
    "chg": 0,
    "chgp": "1.36%",
    "dir": 1,
    "prev_price": "0.30",
    "mcapval": "37.71",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US45408X3089",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "893.75 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/igc-pharma-inc-1155931-215&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is IGC Pharma, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-igc-pharma-inc-technically-bullish-or-bearish-3545892",
        "imagepath": "",
        "date": "2025-09-20 19:20:55",
        "description": "As of 2 September 2025, the technical trend for IGC Pharma, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance, but the weekly RSI is bearish. Bollinger Bands show a mildly bullish trend on both weekly and monthly time frames. The KST is bullish weekly but bearish monthly, and the OBV is bullish monthly with no trend weekly. \n\nIn terms of performance, IGC Pharma has outperformed the S&P 500 over the past week (1.98% vs. 1.05%) and month (8.37% vs. 2.33%), as well as year-to-date (22.59% vs. 12.22%) and over the past year (21.15% vs. 17.14%). However, it has significantly underperformed over the longer terms of 3 years, 5 years, and 10 years. Overall, the current stance is mildly bullish, with mixed signals from various indicators...."
      },
      {
        "title": "Is IGC Pharma, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-igc-pharma-inc-overvalued-or-undervalued-3542563",
        "imagepath": "",
        "date": "2025-09-20 17:56:03",
        "description": "As of 10 August 2023, IGC Pharma, Inc. has moved from a grade of does not qualify to risky. The company is overvalued based on its current financial metrics. Key ratios include a Price to Book Value of 3.90, an EV to EBIT of -2.95, and an EV to EBITDA of -3.21, indicating significant operational challenges and a lack of profitability. In comparison, peers such as Equillium, Inc. have an EV to EBITDA of -4.94, and OncoCyte Corp. stands at -2.13, suggesting that IGC Pharma's valuation is less favorable relative to its peers.\n\nDespite a strong year-to-date return of 22.59% compared to the S&P 500's 12.22%, the overall long-term performance remains concerning, with a 5-year return of -65.39% versus the S&P 500's 96.61%. This discrepancy highlights the risks associated with investing in IGC Pharma, reinforcing the conclusion that the stock is overvalued...."
      }
    ],
    "total": 7,
    "sid": "1155931",
    "stock_news_url": "https://www.marketsmojo.com/news/igc-pharma-inc-1155931"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is IGC Pharma, Inc. technically bullish or bearish?

2025-09-20 19:20:55

As of 2 September 2025, the technical trend for IGC Pharma, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance, but the weekly RSI is bearish. Bollinger Bands show a mildly bullish trend on both weekly and monthly time frames. The KST is bullish weekly but bearish monthly, and the OBV is bullish monthly with no trend weekly. In terms of performance, IGC Pharma has outperformed the S&P 500 over the past week (1.98% vs. 1.05%) and month (8.37% vs. 2.33%), as well as year-to-date (22.59% vs. 12.22%) and over the past year (21.15% vs. 17.14%). However, it has significantly underperformed over the longer terms of 3 years, 5 years, and 10 years. Overall, the current stance is mildly bullish, with mixed signals from various indicators....

Is IGC Pharma, Inc. overvalued or undervalued?

2025-09-20 17:56:03

As of 10 August 2023, IGC Pharma, Inc. has moved from a grade of does not qualify to risky. The company is overvalued based on its current financial metrics. Key ratios include a Price to Book Value of 3.90, an EV to EBIT of -2.95, and an EV to EBITDA of -3.21, indicating significant operational challenges and a lack of profitability. In comparison, peers such as Equillium, Inc. have an EV to EBITDA of -4.94, and OncoCyte Corp. stands at -2.13, suggesting that IGC Pharma's valuation is less favorable relative to its peers. Despite a strong year-to-date return of 22.59% compared to the S&P 500's 12.22%, the overall long-term performance remains concerning, with a 5-year return of -65.39% versus the S&P 500's 96.61%. This discrepancy highlights the risks associated with investing in IGC Pharma, reinforcing the conclusion that the stock is overvalued....

View All News